Chip-Based Blood Test Accurately Diagnoses Heart Attack in Minutes
|
By LabMedica International staff writers Posted on 17 Oct 2024 |

Heart attacks demand immediate medical attention to improve patient outcomes; however, while early diagnosis is crucial, it can be quite challenging—and nearly impossible outside of a clinical environment. Diagnosing heart attacks remains one of the most difficult tasks due to the wide variability of symptoms and subtle biological signals that can be easily overlooked in the early stages of an attack when medical intervention can be most beneficial. Individuals suspected of experiencing a heart attack typically undergo a series of tests to confirm the diagnosis, usually beginning with electrocardiograms that measure the heart's electrical activity—a procedure that takes about five minutes—and blood tests to identify the indicators of a heart attack, where lab results can take at least an hour and often require repetition. A new blood test has now been developed that can diagnose a heart attack in minutes rather than hours, and it has the potential to serve as a tool for first responders and individuals at home.
Researchers at Johns Hopkins University (Baltimore, MD, USA) have published their proof-of-concept work in Advanced Science, which can be modified to detect infectious diseases and cancer biomarkers. The focus of the research has been on developing diagnostic tools through biophotonics, utilizing laser light to identify biomarkers—bodily responses to various conditions, including diseases. In this instance, they applied the technology to detect the earliest signs in the blood that indicate a heart attack. The stand-alone blood test created by the team yields results in just five to seven minutes. They claim it is also more accurate and cost-effective than current methods.
Although initially designed for rapid diagnostic use in a clinical setting, the test could be adapted into a hand-held device for use by first responders in the field or even for personal use at home. Central to the invention is a small chip featuring a groundbreaking nanostructured surface for blood testing. The chip's "metasurface" amplifies electric and magnetic signals during Raman spectroscopy analysis, enabling heart attack biomarkers to be detected in seconds, even at ultra-low concentrations. This tool is sensitive enough to identify heart attack biomarkers that might not be detected by existing tests or might only be recognized later in the course of an attack. While primarily intended for diagnosing heart attacks, the researchers believe the tool could also be modified to detect cancer and infectious diseases. The team plans to refine the blood test further and undertake larger clinical trials in the future.
"We're talking about speed, we're talking about accuracy, and we're talking of the ability to perform measurements outside of a hospital," said Ishan Barman, Professor, Department of Mechanical Engineering. "In the future, we hope this could be made into a hand-held instrument like a Star Trek tricorder, where you have a drop of blood and then, voilà, in a few seconds you have detection."
Latest Technology News
- Noninvasive Sputum Test Detects Early Lung Cancer
- New AI Tool Enables Rapid Treatment Selection in Pediatric Leukemia
- Rapid Biosensor Detects Drug Sensitivity in Breast Tumors
- Breakthrough Mass Spectrometry Design Could Enable Ultra-Low Abundance Detection
- Online Tool Supports Family Screening for Inherited Cancer Risk
- Portable Breath Sensor Detects Pneumonia Biomarkers in Minutes
- New Electronic Pipette Enhances Workflows with Touchscreen Control
- AI Model Outperforms Clinicians in Rare Disease Detection
- AI-Driven Diagnostic Demonstrates High Accuracy in Detecting Periprosthetic Joint Infection
- Blood Test “Clocks” Predict Start of Alzheimer’s Symptoms
- AI-Powered Biomarker Predicts Liver Cancer Risk
Channels
Clinical Chemistry
view channel
AI-Enabled POC Test Quantifies Multiple Cardiac Biomarkers
Cardiovascular diseases are a leading cause of death, responsible for nearly 20 million deaths each year. Timely triage of myocardial infarction and heart failure hinges on rapid cardiac biomarker measurement,... Read moreNext Generation Automated Analyzers Increase Throughput for Clinical Chemistry and Electrolyte Testing
Clinical laboratories continue to face staffing shortages, limited space, and growing test volumes that pressure chemistry and electrolyte workflows. Maintaining rapid turnaround times increasingly depends... Read moreMolecular Diagnostics
view channel
Genome Sequencing Identifies Noncoding Variants Causing Neonatal Diabetes
Neonatal diabetes is a rare form of diabetes that presents in the first six months of life and is driven by genetic changes, yet many affected families still lack definitive diagnoses. Genetic studies... Read more
Genetic Markers Predict GLP-1 Weight-Loss Response and Side Effects
Glucagon-like peptide-1 (GLP-1) receptor agonists such as semaglutide and tirzepatide are now widely used for weight management, yet individual responses vary considerably, with some patients experiencing... Read moreHematology
view channel
Prognostic Tool Guides Personalized Treatment in Rare Blood Cancer
Chronic myelomonocytic leukemia (CMML) is a rare blood cancer in which acquired genetic mutations in bone marrow stem cells drive disease. Stem cell transplantation is the only curative option but carries... Read more
New Platelet Function Assay Enables Monitoring of Antiplatelet Therapy
Monitoring response to antiplatelet therapy remains challenging for many clinical laboratories. Aggregation-based assays and cartridge systems often require specialized personnel, dedicated instruments,... Read moreImmunology
view channelCombined Screening Approach Identifies Early Leprosy Cases
Leprosy remains a significant public health concern, with more than 200,000 new cases reported globally each year and early disease often escaping routine laboratory detection. In its initial phase, bacterial... Read more
Antibody Blood Test Identifies Active TB and Distinguishes Latent Infection
Active tuberculosis (TB) remains a leading cause of death and illness worldwide, yet distinguishing contagious disease from latent infection continues to challenge clinicians. Standard screening tools... Read more
FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas
Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Study Identifies Inflammatory Pathway Driving Immunotherapy Resistance in Bladder Cancer
Bladder cancer remains a prevalent malignancy with variable responses to immune checkpoint inhibitors. Clinicians often observe elevated C-reactive protein and interleukin-6 in affected patients, yet the... Read moreMicrobiology
view channel
Cost-Effective Sampling and Sequencing Workflow Identifies ICU Infection Hotspots
Intensive care units face persistent threats from hospital-acquired infections, increasingly driven by drug-resistant bacteria. Rapidly pinpointing environmental reservoirs and transmission hotspots remains... Read more
New Bacterial Target Identified for Early Detection of Noma
Noma is a rapidly progressing orofacial infection that begins as gingivitis and can destroy oral and facial tissues, primarily affecting young children living in extreme poverty. Without treatment, it... Read morePathology
view channelAI Improves Completeness of Complex Cancer Pathology Reports
Oncology teams increasingly rely on pathology reports that integrate histopathology, immunohistochemistry, and rapidly expanding biomarker testing. As patients live longer and undergo repeated analyses... Read more
AI Tool Predicts Chemotherapy Response in Small Cell Lung Cancer
Small cell lung cancer often presents at an extensive stage and progresses rapidly, leaving little time to tailor first-line therapy. Clinicians currently lack biomarkers to guide which patients will benefit... Read more
Tumor-Specific Biomarker Predicts Neoadjuvant Immunotherapy Response in Gastric Cancer
Gastric cancer is the fifth most common malignancy and the fourth leading cause of cancer mortality worldwide, with China bearing nearly half of the global burden. Only a subset of patients benefit from... Read moreIndustry
view channel
GRAIL Partners with Epic to Integrate Multi-Cancer Test into EHR
GRAIL’s Galleri multi-cancer early detection (MCED) test is being integrated into Epic’s electronic health record (EHR) platform through Epic Aura. The collaboration is designed to let clinicians at interested... Read moreGlobal Partnership Aims to Streamline NGS Tumor Profiling in Oncology Trials
CellCarta and Pillar Biosciences announced a global, multi-year strategic partnership on April 2, 2026 to broaden access to operationally streamlined next-generation sequencing (NGS) tumor profiling for... Read more







